10-K: Curanex Pharmaceuticals Advances Phyto-N, Reports $4.2M Net Loss

Curanex Pharmaceuticals Inc. completed its IPO, raised $15.3 million, and is progressing its lead botanical drug candidate, Phyto-N, into clinical development for inflammatory diseases, despite reporting a $4.2 million net loss and internal control weaknesses.

Summary

• Curanex Pharmaceuticals Inc. completed its Initial Public Offering (IPO) on August 27, 2025, raising gross proceeds of $15.0 million, with an additional $2.25 million from the underwriters' over-allotment option on September 12, 2025, totaling approximately $15.3 million in net proceeds.
• The company reported a net loss of $4.2 million for the year ended December 31, 2025, a significant increase from the $361,506 net loss in 2024, primarily due to expanded research and development activities and public company operating costs.
• Research and Development (R&D) expenses surged to $2,985,873 in 2025 from $74,676 in 2024, reflecting increased investment in IND-enabling studies for its lead botanical drug candidate, Phyto-N.
• General and Administrative (G&A) expenses also rose to $1,253,203 in 2025 from $290,386 in 2024, driven by higher personnel costs and professional fees associated with operating as a public company.
• Curanex is a developmental stage pharmaceutical company focused on botanical drugs for inflammatory diseases, with Phyto-N targeting ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease (NAFLD), and gout.
• Preclinical studies for Phyto-N in animal models have shown positive results across all six target indications, with no observed adverse or severe adverse events in treated animals.
• A pilot-scale batch of Phyto-N was successfully manufactured under Good Manufacturing Practice (GMP) standards in February 2026, intended for IND-enabling nonclinical studies.
• The company targets submitting an Investigational New Drug (IND) application for ulcerative colitis in the fourth quarter of 2026, with Phase I clinical trials planned to commence in Australia shortly thereafter.
• Management concluded that internal control over financial reporting was not effective as of December 31, 2025, due to material weaknesses including a lack of internal controls, insufficient US GAAP experienced personnel, and an inadequate bookkeeping system.
• Curanex received a Nasdaq deficiency notice on November 5, 2025, for its common stock trading below the $1.00 minimum bid price requirement, with a compliance period until May 4, 2026.
• The company's founders, Jun Liu and Dian Ying Jing, along with their son Chang Liu, beneficially own approximately 67.9% of the outstanding common stock and 100% of the Series A Preferred Stock, which carries 40% of the total voting power.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed bag. While the IPO provided much-needed capital and preclinical data is encouraging, the substantial net loss, internal control weaknesses, and Nasdaq delisting risk present significant challenges. The long, uncertain, and expensive path for botanical drug approval further adds to the risk profile.

Positives

• Successfully completed its Initial Public Offering (IPO) on August 27, 2025, raising approximately $15.3 million in net proceeds, significantly improving its cash position to $4,973,134 as of December 31, 2025.
• Phyto-N, the lead botanical drug candidate, has shown positive results in preclinical animal models across six inflammatory diseases: ulcerative colitis, atopic dermatitis, COVID-19, diabetes, NAFLD, and gout, with no observed adverse events in treated animals.
• Successfully completed a GMP pilot-scale batch of Phyto-N in February 2026, a crucial step for advancing towards IND submission and clinical trials.
• The company has a clear roadmap for IND submission for ulcerative colitis in Q4 2026 and plans to initiate Phase I clinical trials in Australia shortly thereafter.
• Acquired four provisional patent applications and 8 research and development animal studies and reports from Duraviva Pharma Inc. on June 17, 2024, strengthening its intellectual property and research foundation.
• Established a Scientific Advisory Board in March 2026, comprising four experienced advisors to provide scientific guidance across R&D, preclinical study design, IND preparation, clinical trials, and intellectual property strategy.
• Management believes existing cash and cash equivalents are sufficient to fund operating expenses and capital requirements for at least the next twelve months.

Negatives

• Reported a significant net loss of $4.2 million for the year ended December 31, 2025, an increase from $361,506 in 2024, indicating substantial cash burn in its developmental stage.
• Has a limited operating history and no revenue from product sales to date, making future prospects difficult to evaluate and increasing inherent risks of an early-stage company.
• Management concluded that internal control over financial reporting was not effective as of December 31, 2025, due to material weaknesses, including a lack of internal controls, insufficient US GAAP experienced personnel, and an inadequate bookkeeping system.
• Received a Nasdaq deficiency notice on November 5, 2025, for failing to meet the minimum $1.00 bid price requirement, with a compliance deadline of May 4, 2026, risking potential delisting.
• The company estimates it will require over $150 million to execute its full business plan through FDA approval and product launch, with no assurance of obtaining this additional financing on acceptable terms.
• The development and approval process for botanical drugs involves unique challenges, including complex composition, standardization, pharmacokinetics, intellectual property protection, and manufacturing complexities, with only four such drugs having received FDA approval to date.
• The founders and their immediate family beneficially own approximately 67.9% of common stock and 100% of Series A Preferred Stock (40% voting power), allowing them to exert significant control over corporate matters, which may not always align with other shareholders' interests.
• The company has never paid cash dividends and does not anticipate doing so in the foreseeable future, meaning investors must rely solely on stock price appreciation for returns.

Risks

• Limited operating history and no commercial products, making future prospects uncertain and increasing inherent risks of a small, early-stage pharmaceutical company.
• Significant capital requirements (over $150 million estimated for full business plan through FDA approval and launch), with no assurance of obtaining additional financing on acceptable terms, leading to potential dilution or operational curtailment.
• High risk of failure in clinical trials; promising early-stage results may not be predictive of success in later stages, potentially impairing commercial prospects for Phyto-N.
• Inability to obtain and maintain effective patent protection for Phyto-N, as provisional patent applications expired and there is no assurance the international PCT application will result in successful utility patent registration.
• The regulatory approval processes for botanical drugs are lengthy, expensive, inherently unpredictable, and involve unique challenges (complex composition, standardization, limited precedent), increasing the risk of delays or failure to obtain approval.
• Dependence on third-party manufacturers for clinical drug supplies, exposing the company to risks of supply delays, quality issues, or increased costs.
• Failure to attract, retain, and motivate highly skilled personnel, including senior management, could harm business operations.
• Management lacks prior experience as senior management of a public company, potentially leading to challenges in complying with complex public company obligations and diverting attention from day-to-day operations.
• Material weaknesses in internal control over financial reporting (lack of controls, insufficient US GAAP experienced personnel, inadequate bookkeeping system) as of December 31, 2025, which could lead to material misstatements and harm investor confidence.
• Nasdaq minimum bid price requirement deficiency, with potential delisting if compliance is not regained by May 4, 2026, which could impair stock liquidity and ability to raise capital.
• Potential for the common stock to become subject to "penny stock" rules if delisted, making it more difficult to sell shares.
• Significant control exerted by founders and their family (67.9% common stock, 100% Series A Preferred Stock with 40% voting power) over shareholder matters, potentially leading to decisions not aligned with other shareholders.
• Exposure to cybersecurity and data leakage risks, which could compromise sensitive information, disrupt operations, and result in financial or reputational harm.
• Disruptions from natural disasters, industrial accidents, epidemics, pandemics, war, and acts of terrorism, or geopolitical instability (e.g., Russia-Ukraine, Middle East conflicts) could adversely affect operations, supply chain, and financial results.
• Changes to U.S. tariff and import/export regulations and inflation may adversely affect operations and financial results.
• Potential for legal proceedings, including intellectual property infringement claims, which could result in substantial costs and diversion of management attention.

Future Outlook

Curanex Pharmaceuticals plans to submit its first Investigational New Drug (IND) application for Phyto-N for ulcerative colitis in the fourth quarter of 2026, with Phase I clinical trials expected to commence in Australia shortly thereafter. Contingent on successful trials and funding, the company intends to pursue additional Phase II trials for other high-value indications or license them to third parties. The company aims to continue investing in translational research to optimize clinical trial design and improve success rates, but acknowledges the uncertainty of clinical development timelines, FDA approval, and securing sufficient future funding.

Management Comments

• Our mission is to address significant unmet medical needs and improve patients lives by harnessing the power of natural substances.
• We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections.
• We believe that the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging a proposal to acquire us because negotiation of these proposals could result in an improvement of their terms.
• We believe that Phyto-N has a potential ability to target multiple disease pathways and regulate various pathological processes, and if these efforts are successful and lead to regulatory approval of Phyto-N determined by clinical trials, will make it a pipeline in a product that will address unmet needs in complex and hard-to-treat conditions.
• We believe that our distinctive approach, combining the power of nature with scientific research and development, will set us apart in the pharmaceutical industry and positions us for long-term success.
• We believe that our existing cash and cash equivalents will be sufficient to fund our operating expenses and capital requirements for at least the next twelve months from the date of this Annual Report on Form 10-K.
• We are committed to Bringing hope and healing through the wisdom of plants.

Industry Context

StockSavvy.ai notes that Curanex Pharmaceuticals operates in the rapidly growing global market for inflammatory disease treatments, valued at approximately $26.7 billion in 2023 for IBD alone and projected to reach $50 billion by 2034. The botanical and plant-derived drugs market, including phytomedicine, is also expanding rapidly, reaching around $34 billion, driven by consumer preferences for natural and holistic health solutions. Curanex's focus on botanical drugs like Phyto-N positions it in a niche with high potential but also significant regulatory hurdles, as evidenced by only four FDA-approved botanical drugs to date. The company's multi-target approach for Phyto-N could offer a competitive advantage over single-target agents, similar to how biologics like Remicade or Humira dominate the IBD market but often have limitations. However, the competitive landscape is intense, with major pharmaceutical companies like AbbVie, Janssen Biotech, Takeda Pharmaceutical, Pfizer, Merck, Novartis, and Boehringer Ingelheim investing heavily in novel biologics and R&D.

Comparison to Industry Standards

• Curanex's lead candidate, Phyto-N, is a botanical drug, a category with limited FDA precedent (only four approvals: Veregen, Mytesi, Filsuvez, NexoBrid), indicating a higher regulatory hurdle compared to conventional small molecule drugs or biologics.
• In ulcerative colitis, Phyto-N aims to address limitations of current treatments like corticosteroids, immunomodulators, and biologics (e.g., anti-TNF agents like Remicade, Humira, or anti-integrin agents like Entyvio), which often have side effects, inadequate control, or administration challenges. Phyto-N's potential multi-target mechanism could differentiate it from single-target biologics like Dupilumab for atopic dermatitis.
• For NAFLD, the recent FDA approval of Rezdiffra (resmetirom) by Madrigal Pharmaceuticals in March 2024 sets a new benchmark, but it also comes with side effects and drug interaction warnings. Phyto-N's preclinical data suggests a multi-pathway approach that could offer an alternative, but direct clinical comparisons are yet to be conducted.
• In gout treatment, Phyto-N's potential to reduce inflammatory mediators and improve renal function in animal models could offer an alternative to existing therapies like Febuxostat, which carries a black box warning for cardiovascular risk.
• The company's reliance on third-party manufacturers for clinical drug supplies is a common industry practice for developmental-stage biotechs, but it introduces supply chain risks that larger, integrated pharmaceutical companies might mitigate through in-house production.
• The identified material weaknesses in internal controls over financial reporting are below industry best practices for public companies, especially post-IPO, and require significant remediation efforts to meet SEC and Nasdaq standards.

Management Changes

Corporate Governance

Legal Proceedings

• No pending legal proceedings to which the company or its directors, officers, or affiliates are a party adverse to the company.

Related Party Transactions

• On June 17, 2024, Curanex entered into an Asset Purchase Agreement with Duraviva Pharma Inc., a related party (majority shareholders are common), acquiring four provisional patent applications and eight R&D animal study reports for $730,000 consideration and 23,400,000 shares of common stock.
• In February and May 2025, the company received two $200,000 loans (total $400,000) from Dian Ying Jing, the Secretary and spouse of the CEO, at 4.34% interest, which were fully repaid in September 2025.
• On January 1, 2025, the company assumed an office lease from Duraviva Pharma Inc.

Stakeholder Impact

• Shareholders: Potential for significant dilution if additional capital raises are equity-based; risk of delisting from Nasdaq could impair liquidity and market price; founders' significant control may not always align with minority shareholder interests; no anticipated dividends.
• Employees: Formalized employment agreements for CEO and COO provide stability; eligibility for equity incentive plans offers potential upside; company's growth strategy could lead to increased hiring.
• Customers (future): If Phyto-N is successfully developed and approved, it could offer new treatment options for patients suffering from inflammatory diseases, addressing unmet medical needs.
• Creditors: Repayment of related-party loans in September 2025 indicates a commitment to debt obligations; however, the need for substantial future financing could impact creditworthiness.
• Regulatory Bodies: The company is committed to complying with FDA and other regulatory standards, which is crucial for product approval and market access.

Next Steps

• Initiate formal GLP toxicology and pharmacokinetic studies for Phyto-N.
• Submit an Investigational New Drug (IND) application for ulcerative colitis in Q4 2026.
• Initiate Phase I clinical trials for ulcerative colitis in Australia in Q4 2026, subject to regulatory clearance.
• Potentially initiate additional Phase II trials for other indications (atopic dermatitis, COVID-19, diabetes, NAFLD, gout) or license them out, contingent on ulcerative colitis trial success and funding.
• Continue translational research to elucidate mechanisms of action, biomarkers, and patient stratification strategies for Phyto-N.
• Actively identify and isolate active chemical compounds from Phyto-N for potential small molecule drug development, aiming to conclude this research prior to IND filing.
• Remediate material weaknesses in internal control over financial reporting by assessing finance and accounting resources, centralizing processes, developing training, and implementing compensating controls.
• Regain compliance with Nasdaq's minimum bid price requirement by May 4, 2026.

Key Dates

Recommendation

Curanex Pharmaceuticals presents a high-risk, high-reward profile. The successful IPO and promising preclinical data for Phyto-N across multiple indications are positive catalysts, suggesting significant long-term potential if clinical trials succeed. However, the substantial net loss, identified material weaknesses in internal controls, and the Nasdaq minimum bid price deficiency introduce considerable near-term uncertainty and operational risk. The inherent challenges and lengthy timeline for botanical drug development, coupled with the need for significant future capital, warrant a cautious approach. A 'hold' recommendation is appropriate for investors who are comfortable with high risk and have a long-term horizon, allowing time for the company to address its operational and compliance issues and demonstrate further clinical progress, particularly with the upcoming IND submission and Phase I trials.

Keywords

Curanex Pharmaceuticals, Phyto-N, Botanical Drug, Inflammatory Diseases, Ulcerative Colitis, Atopic Dermatitis, COVID-19 Treatment, Diabetes Treatment, NAFLD Treatment, Gout Treatment, Preclinical Studies, IND Application, Clinical Trials, FDA Approval, Pharmaceutical Development, Biotechnology, SEC Filing, 10-K, Nasdaq Listing, Internal Controls, Capital Raise, Intellectual Property, Drug Discovery, Corporate Governance